Literature DB >> 12487806

Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy.

Coral-Ann M Almeida1, Patricia Price, Martyn A H French.   

Abstract

Immune activation associated with HIV infection declines after highly active antiretroviral therapy (HAART), but may persist or recur in some patients. It is not clear whether this reflects a resurgence of HIV replication or another cause of immune activation, such as inflammatory reactions to opportunistic pathogens (immune restoration disease [IRD]). Here, we studied plasma and cellular immune activation markers in adult HIV-1 patients who had received HAART for >12 months and maintained plasma HIV RNA levels of <400 copies/ml for >6 months. Plasma interleukin 1 receptor antagonist and tumor necrosis factor receptor I levels were similar in patients and HIV-negative control subjects, but the highest levels occurred mainly in patients with a history of IRD. In contrast, expression of HLA-DR and CD38 on monocytes and of HLA-DR on CD8(+) T cells was higher in patients than in control subjects. Thus, cellular markers of immune activation are abnormal in some patients with a good virological response to HAART, and abnormalities of plasma immune activation markers correlate with a history of IRD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12487806     DOI: 10.1089/088922202320935429

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus?

Authors:  Fathiah S Amran; Kyungchul Kim; Andrew Lim; Rachel Thomson; Silvia Lee; Grant Waterer; Patricia Price
Journal:  J Clin Immunol       Date:  2016-01-13       Impact factor: 8.317

2.  Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART.

Authors:  Kate Burgess; Patricia Price; Ian R James; Shelley F Stone; Niamh M Keane; Andrew Y F Lim; John R Warmington; Martyn A French
Journal:  J Clin Immunol       Date:  2006-03-28       Impact factor: 8.317

Review 3.  Mechanistic insights on immunosenescence and chronic immune activation in HIV-tuberculosis co-infection.

Authors:  Esaki M Shankar; Vijayakumar Velu; Adeeba Kamarulzaman; Marie Larsson
Journal:  World J Virol       Date:  2015-02-12

Review 4.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

Review 5.  Role of immune activation in progression to AIDS.

Authors:  Netanya S Utay; Peter W Hunt
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

6.  HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.

Authors:  Theodoros Kelesidis; Otto O Yang; Judith S Currier; Kaveh Navab; Alan M Fogelman; Mohamad Navab
Journal:  Lipids Health Dis       Date:  2011-02-23       Impact factor: 3.876

7.  High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.

Authors:  Damalie Nakanjako; Isaac Ssewanyana; Harriet Mayanja-Kizza; Agnes Kiragga; Robert Colebunders; Yukari C Manabe; Rose Nabatanzi; Moses R Kamya; Huyen Cao
Journal:  BMC Infect Dis       Date:  2011-02-08       Impact factor: 3.090

8.  The immunological footprint of CMV in HIV-1 patients stable on long-term ART.

Authors:  Jacquita S Affandi; Jacinta Montgomery; Samantha J Brunt; David Nolan; Patricia Price
Journal:  Immun Ageing       Date:  2015-10-01       Impact factor: 6.400

9.  Residual immune activation in HIV-Infected individuals expands monocytic-myeloid derived suppressor cells.

Authors:  Ritesh Singh; Mouli Chakraborty; Anuradha Gautam; Suman K Roy; Indranil Halder; Jamie Barber; Ankita Garg
Journal:  Cell Immunol       Date:  2021-02-10       Impact factor: 4.868

10.  Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults.

Authors:  Theodoros Kelesidis; Otto O Yang; Michelle A Kendall; Howard N Hodis; Judith S Currier
Journal:  Lipids Health Dis       Date:  2013-03-05       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.